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ABSTRACT
Objective: Human intravenous immunoglobulin manu-
factured with chromatography and caprylate methods
(IGIV-C, 10%) was associated with a reduction in vali-
dated infections (pneumonia and sinusitis) compared with
treatment with a licensed immunoglobulin product man-
ufactured using standard solvent-detergent methods
(IGIV-SD™, 10%) in participants with primary humoral
immunodeﬁciency disorder (PIDD). Our objective was to
determine the cost-consequences of using IGIV-C instead
of IGIV-SD.
Methods: Economic analysis of a double-blind, rand-
omized, clinical trial was used. Participants were ran-
domly assigned to IGIV-C (N = 87) or IGIV-SD (N = 85)
and monitored for the development of validated infec-
tions over the course of 9 months. Consumed resources
were enumerated including cost of physician and emer-
gency room visits, medications (prescription and over-the-
counter), work productivity losses, and hospitalizations.
Resource data was obtained from case report forms,
patient diaries and the trial medication database. Because
the amount of IGIV-SD used exceeded that of IGIV-C
(nonstatistically signiﬁcant difference) and the products
are equivalently priced, we conservatively excluded inves-
tigational product acquisition cost to avoid artiﬁcially
biasing incremental cost differences. We used a societal
perspective with indirect costs, measured in 2003 US dol-
lars. Pricing of both IGIV products is anticipated to be
equivalent.
Results: In a multivariate analysis, annual mean per
participant costs were signiﬁcantly lower between those
receiving IGIV-C compared with IGIV-SD for prescription
medications [–$302, 95% conﬁdence interval (CI) –$598
to  –$6],  hospitalization  (–$1454,  95%  CI  –$1828  to
–$1080)  and  total  costs  (–$1304,  95%  CI  –$1867  to
–$742). Costs associated with lost work productivity and
physician visits were similar in both groups (P > 0.10). In
sensitivity analyses, varying costs of concomitant medica-
tions, hospitalization and outpatient care, did not signif-
icantly change our results.
Conclusion: IGIV-C is cost-saving compared with IGIV-
SD among persons with PIDD.
Keywords: economics, immunoglobulin, manufacturing,
primary immune deﬁciency, sinusitis.
Introduction
Polyvalent intravenous IgG (IGIV) is manufactured
from human plasma, pooled from thousands of
donors  and  used  to  treat  a  variety  of  approved
and off-label conditions such as primary humoral
immunodeﬁciency disorder (PIDD), idiopathic
thrombocytopenic purpura, multiple sclerosis,
chronic inﬂammatory demyelinating polyneuropa-
thies, bullous skin diseases and many others [1]. To
create the perfect therapeutic IGIV solution, manu-
facturing processes need to maintain the integrity
and biologic activity of each IgG molecule, while
simultaneously removing unwanted viruses, prions
and other pathogens. Reﬁnements in manufacturing
over the years have led to third-generation IGIV
products many of which use solvent/detergent (SD)
methods for improving the safety of plasma-derived
products and isolation of IgG [2,3]. Nevertheless,
SD methods can alter immunoglobulin yield and
function [4].
Recently, the US Food and Drug Administration
approved a new IGIV product (IGIV-C, 10%,
Gamunex®, Bayer Health Care, Biological Products
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Division, LLC., Research Triangle Park, NC) that is
manufactured with an entirely new process using
large scale chromatography and caprylate tech-
niques (for puriﬁcation and viral inactivation).
Compared with an IGIV manufactured from SD
methods (Gamimune N™, also Bayer Health Care,
IGIV-SD, 10%), IGIV-C demonstrated increased
IGIV yield from plasma, more rapid viral inactiva-
tion kinetics and an improved physiological IgG
subclass distribution (speciﬁcally higher IgG4 lev-
els) [4–6]. Moreover, in a randomized, double-
blind, head-to-head clinical trial among patients
with PIDD, IGIV-C was associated with a reduction
in the percentage of PIDD patients with at least one
validated sinopulmonary infection, translating into
a statistically signiﬁcant decrease in annualized
infection rate compared with IGIV-SD [7].
Primary humoral immunodeﬁciency disorder
patients typically require lifelong, periodic, replace-
ment therapy with IGIV to prevent infections from
encapsulated bacteria. The standard of care for
PIDD patients is IGIV infusions every 3 to 4 weeks,
generally between 300 and 600 mg/kg [8] and the
annual per patient costs are high [9]. Although there
is support for the clinical advantages seen in PIDD,
the cost consequences of using the new IGIV-C
product has not been investigated.
To better understand the economic impact of
using differently manufactured IGIV products, we
examined the cost consequences of using IGIV-C
compared with IGIV-SD in patients with PIDD.
Given the high morbidity and costs associated with
sinopulmonary infections commonly associated
with PIDD, payers and providers should choose a
treatment strategy that maximizes value.
Methods
Study Design
We conducted a retrospective economic analysis of
the randomized controlled trial comparing the efﬁ-
cacy and safety of IGIV-C versus IGIV-SD in the
treatment of PIDD. A complete description of the
clinical trial has been previously published [7].
Brieﬂy, the trial was conducted at 25 centers in the
United States and Canada from March 8, 1999 to
June 19, 2000. A total of 172 participants were
enrolled (87 were assigned to IGIV-C; 85 to IGIV-
SD). All participants had a conﬁrmed diagnosis of
PIDD as deﬁned by World Health Organization
(WHO) criteria, including but not limited to
congenital agammaglobulinemia or hypogamma-
globulinemia including X-linked and autosomal
forms, common variable immunodeﬁciency, severe
combined immunodeﬁciency, and Wiskott–Aldrich
syndrome. The participants were followed for
9 months from the day of ﬁrst infusion. Tables 1
and 2 summarize data from the clinical trial. Demo-
graphic differences were not statistically signiﬁcant.
Table 1 Demographic characteristics of primary humoral immunodeﬁciency participants enrolled in clinical trial on an intent-
to-treat basis
IGIV-C (n = 87) IGIV-SD (n = 85)
Age, mean ± SD 34.9 ± 20.5 29.8 ± 18.3
Sex, n (%) men 60 (69) 49 (58)
Ethnicity, n (%) white 75 (86) 71 (84)
Weight (kg), mean ± SD 66.4 ± 25.7 61.3 ± 26.4
Height (cm), mean ± SD 162.4 ± 22.8 158.7 ± 23.3
Pre-existing bronchiectasis, n (%) with 17 (20) 18 (21)
3-week dosing schedule for IV, n (%) with 10 (11) 18 (21)
Previous IGIV dose (mg/kg), mean ± SD 432.7 ± 122.6 454.6 ± 125.1
Duration of follow-up in trial, days ± SD 256.7 ± 66.0 266 ± 53.3
Total number of baseline prescriptions 308 307
None of the above differences were statistically signiﬁcant.
Table 2 Efﬁcacy analysis of IGIV-C compared with IGIV-SD, 10%
IGIV-C (n = 73) IGIV-SD (n = 73) P value
Validated infections* 9 (12%) 17 (23%) P = 0.06
Pneumonia 0 2 (3%) NS
Acute sinusitis 4 (5%) 10 (14%) P = 0.09
Acute exacerbation of chronic sinusitis 5 (7%) 6 (8%) NS
Annualized validated infection rate (per 100 person-years) 18 43 P < 0.05
*Validated infections are pneumonia, acute sinusitis and acute exacerbation of chronic sinusitis.
NS, not statistically signiﬁcant P > 0.1.
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The primary clinical end point was the propor-
tion of participants experiencing validated infection
(pneumonia, sinusitis and acute exacerbation of
chronic sinusitis). Secondary end points included
annual validated infection rate. The study found
fewer validated infections among participants
receiving IGIV-C versus IGIV-SD and a statistically
signiﬁcant reduction in the annual validated infec-
tion rate (Table 2).
Costing Approach
Our economic analysis included all participants
randomized to treatment (intent-to-treat basis). The
primary outcome was the incremental costs of IGIV-
C compared with IGIV-SD. The cost for each par-
ticipant was calculated in a three-stage process: 1)
medical resources use and lost work productivity by
each participant during the study period were tab-
ulated; 2) a standard unit cost was assigned to each
type of resource; and 3) the quantity of each
resource used by a participant was multiplied by the
cost of that resource. Unit costs were measured in
2003 US dollars.
From the clinical trial case report forms, partic-
ipant diaries or the trial medication database, we
enumerated the number of physician or emergency
room visits, dose and quantity of incident medica-
tions, number of missed days of school or work,
and number of hospitalizations. We further classi-
ﬁed medications as to whether they were for vali-
dated infections (occurring 2 weeks from the point
of a validated infection), clinically deﬁned (nonval-
idated) infections (same method as per validated
infections), adverse events (on the same day as
adverse event) and “all other” medications. The
prescription database also recorded over-the-coun-
ter drugs and vitamins used by patients. Hospitali-
zations were considered as adverse events by clinical
investigators and documented during periodic fol-
low-up visit (principal diagnosis listed only) or by
participant diary (days hospitalized listed only). In
the primary analysis, we estimated costs of all hos-
pitalizations regardless of causality.
Assignment of costs. Physician ofﬁce and emer-
gency room visits were monetized using Current
Procedural Terminology (CPT) coding for a level 3
physician and emergency room visit evaluation and
management code [10]. We assumed that each diary
entry corresponded to one visit. Because the diaries
did not distinguish whether a visit was for a physi-
cian ofﬁce or an emergency room visit, we assumed
a 50–50 distribution of each. In sensitivity analyses,
we altered this assumption by using an 80%
physician ofﬁce and a 20% emergency room visit
distribution.
Incident medications were valued using 95% of
the average wholesale price listed in the 2003
Thompson’s Redbook [11]. If dosage or duration
information on the prescriptions were incomplete
(11% of prescriptions), costs were imputed using
the average costs of the known prescriptions within
the same medication class. In sensitivity analyses,
we valued medications using 80% of average
wholesale price instead of the aforementioned 95%.
Because the amount of IGIV-SD used during the
trial exceeded that of IGIV-C (nonstatistically sig-
niﬁcant difference) and the products are equiva-
lently priced (personal communication, Bayer by
Bayer Health Care, Biological Products Division,
LLC.), we conservatively excluded investigational
product acquisition cost to avoid artiﬁcially biasing
incremental cost differences. For example, using an
acquisition cost of $52 per gram would have added
an extra $20,000 in total costs in favor of IGIV-C
for what would be best described as random varia-
tion among study groups.
We valued each day of missed school or work in
participant diaries by multiplying the median
hourly wage in the United States (all nonfarm work-
ers from the bureau of labor statistics) by 8 hours of
lost productivity. This approach assumes that all
working participants or one caregiver per school-
attending participant will miss 8 hours of work. It
also assumes that lost productivity will not be
replaced later in time. In sensitivity analyses, we
decreased these costs by 50% (4 hours of work
missed instead of 8 hours).
For estimating cost of hospitalizations, we iden-
tiﬁed the median charge for the principal diagnosis
found in the Healthcare Cost and Utilization Project
(HCUP), a national inpatient database, and multi-
plied it with a cost-to-charge ratio of 0.56 (national
estimate as per HCUP database) [12]. For hospital-
izations recorded only in participant diaries (32%
of hospitalizations), we multiplied the average cost
per inpatient day among all of the other hospitali-
zations in the trial by the length of stay recorded in
the diaries. In sensitivity analyses, we limited costs
to those hospitalizations attributed by clinical inves-
tigator as “possibly” or “probably” related to study
drug, thereby omitting all diary recorded and non-
PIDD related hospitalizations.
Statistical analysis. Costs were computed by sum-
ming costs across each resource category for each
participant. Because some participants did not have
any resource utilization for some of the cost cate-
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gories (zero costs) and for others the frequency of
nonzero costs were not normally distributed, we
used the two-part model multivariate method
described by Blough et al. for inferential analyses
[13]. Brieﬂy, this statistical approach uses a probit
model to examine the probability of having a
nonzero cost by each study group and uses a gen-
eralized linear model to examine the non-normal
costs distribution among those with nonzero costs.
The model uses a maximum likelihood estimation
approach and combines the standards errors iso-
lated from both parts of the model to estimate the
prediction error [13]. This approach has the advan-
tage of incorporating all patient data, which is non-
normal and has a bimodal cost distribution (zero
mass peak and nonzero peak). We performed a mul-
tivariate analysis adjusting for age, sex, presence of
bronchiectasis, weight, height, duration in trial and
average dose of IGIV before entering study. Statis-
tical analysis was performed using STATA software,
Version 7 (StataCorp LP, College Station, TX).
Results
The 87 participants who received IGIV-C had lower
resource use for physician and emergency room vis-
its (26 fewer visits), incident medications (200 fewer
prescriptions), hospitalizations (eight fewer hospi-
talizations), than the 85 participants who received
IGIV-SD (Table 3). Participants in the IGIV-C group
reported 240 days of missed school or work
(productivity losses) compared with 230 among
those receiving IGIV-SD. The IGIV-C group had
lower unadjusted costs per participants associated
with incident medications (D$307), hospitalizations
(D$954), physician ofﬁce and emergency room
(D$41) and total costs (D$1294) than the IGIV-SD
group. For all medications, per participant costs of
medications for validated and nonvalidated infec-
tions were lower in the IGIV-C (D$38 for validated
infections and D$80 for nonvalidated infections)
than the IGIV-SD group. Per participant productiv-
ity costs were similar for both groups ($426 IGIV-C;
$418 IGIV-SD group).
In a multivariate analysis (Fig. 1), we found a
statistically signiﬁcant reduction in the average
participant costs between those receiving IGIV-C
compared with IGIV –S/D for prescription medica-
tions [D$302, 95% conﬁdence interval (CI) –$598
to –$6], hospitalization (D$1454, 95% CI –$1828
to  –$1080)  and  total  costs  (D$1304,  95%  CI
–$1867 to –$742). Participant costs associated with
productivity and physician visits were similar for
both groups and not statistically signiﬁcant.
Sensitivity Analyses
In sensitivity analyses (Table 4), we changed several
costing methods such as having a physician to
emergency room visit ratio of 50:50–80:20 in favor
of physician visits, costing prescriptions using 95%
of average wholesale price to 80% of average
wholesale price, reducing 8 hours of work missed
to 4 hours and from including all hospitalizations to
only those attributed as possibly or probably related
to the study drug. In all of the sensitivity analyses,
the average participant cost differences between the
study groups remained statistically signiﬁcant in
favor of the IGIV-C-treated group. If we made all
assumption changes simultaneously, the average
cost savings for the IGIV-C recipients was lower but
remained  statistically  signiﬁcant  (D$796,  95%  CI
–$556, –$1036).
Table 3 Frequency of resource use, total costs, and cost differences by participants receiving IGIV-C and IGIV-SD in the 9-
month trial
Total events/resources used Unadjusted cost per participant ($)
IGIV-C (n = 87) IGIV-SD (n = 85) IGIV-C (n = 87) IGIV-SD (n = 85) Difference*
Physician ofﬁce and ER total visits 148 174 200 240 41
Incident prescriptions, total 876 1076 1149 1456 307
Prescriptions for validated infections 19 39 21 58 38
Prescriptions for nonvalidated infections 269 344 464 544 80
Prescriptions for adverse events 15 16 10 6 4
Prescriptions for all other medications 573 677 659 850 191
Productivity, self-reported days missed 240 230 426 418 8
Hospitalizations 26 34 1197 2152 954
Hospitalizations attributable to IGIV 1 7 58 561 503
Totals for study (9 months duration) 2167 2597 2971 4265 1294
*Using student’s t test, none of the differences between both groups in the unadjusted analyses were statistically signiﬁcant (P < 0.05). Nevertheless, the t test method
is inaccurate because the cost distribution is not normal. Furthermore, many patients had zero costs—creating a bimodal distribution (large zero mass), therefore,
we used a 2-part model, to examine statistical differences between groups (see Fig. 1), which also displays the 95% conﬁdence interval.
ER, emergency room.
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Because the incremental costs per participant
were statistically lower and the clinical trial results
showed  a  corresponding  reduction  in  infections
for the IGIV-C group than the IGIV-SD recipients,
IGIV-C, in cost-effectiveness parlance, is a domi-
nant strategy compared with IGIV-SD (cost saving
and more efﬁcacious).
Discussion
Under a similar acquisition cost scenario, we found
that participants receiving IGIV-C had lower costs
associated with new prescription medications, hos-
pitalizations and total costs than those receiving
IGIV-SD. Among the various cost categories consid-
ered, hospitalizations were the major source of cost
savings for PIDD patients in the IGIV-C group. This
is not surprising because these immuno-compro-
mised populations are at risk of acquiring infections
from bacteria and therefore are more apt to be hos-
pitalized than the general populace. When using
extremely conservative assumptions for costing hos-
pitalizations the cost differences between the groups
remained statistically signiﬁcant in favor of the
IGIV-C recipients. In addition, pharmacy costs were
also lower. Given that therapeutic moiety, IgG, is
the same among all immunoglobulin products,
these results strongly suggest that manufacturing
processes can result in meaningful clinical and eco-
nomic differences.
Switches from intramuscular immunoglobulin
(IGIM) to IGIV provide historical precedents that
the process of immunoglobulin manufacturing can
lead to clinical and economic improvements in the
treatment of patients with PIDD. In a randomized
controlled trial, Nolte et al. observed fewer acute
infections per year with IGIV compared with IGIM
[14]. In a nonrandomized trial, Bernatowska et al.
observed reduced infection days per year with high-
dose IGIV compared with low dose IGIV [15]. In
that study, clinical improvement was correlated
with higher serum concentrations of immunoglob-
Figure 1 Multivariate cost per participant
differences receiving IGIV-C versus IGIV-SD in
the 9-month trial. Cost differences among par-
ticipants receiving IGIV-C and IGIV-SD. Using
a two-part model, we adjusted for age, sex,
presence of bronchiectasis, weight, height,
duration in trial and average dose of IGIV
before entering study. *Patients receiving
IGIV-C on average, had lower prescription
costs (–$302, 95% CI –$598 to –$6), lower
hospitalization  costs  (–$1454,  95%  CI
–$1828  to  –$1080)  and  lower  total  costs
(–$1304, 95% CI –$1867 to –$742) than
patients receiving IGIV-SD (P < 0.05). Physi-
cian and emergency room and productivity
costs were similar.
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Table 4 Sensitivity analysis: changes to subcosts and total costs using different costing methods over 9 months study duration
Change in costing methods—
sensitivity analysis
Change to subcosts Change to total costs 
Per participant 
cost differences
(IGIV-C – IGIV-SD) ($)  95% CI
Per participant 
cost  differences
(IGIV-C – IGIV-SD) ($)  95% CI
Change physician: ER visit ratio from 
50%-50% to 80%-20%
-34* (-59 to -9) -1264* (-1804 to -724)
Change prescription costs from 95% 
to 80% of AWP
-254* (-503 to -5) -1224* (-1730 to -718)
Change missed days of work from 
8 h to 4 h
-7 (-30 to 15) -1279* (-1824 to -734)
Cost hospitalizations attributable to
IGIV instead of all hospitalizations
-957* (-1364 to 550) -847* (-1183 to -512)
Make all of the aforementioned
changes simultaneously
— — -796* (-1036 to -556)
*P < 0.05.
AWP, average wholesale price.
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ulins. Finally, compared with historical rates with
IGIM, Cunningham-Rundles et al. found reduced
sick days per year and antibiotic usage after patients
were switched from IGIM to IGIV [16].
Until recently, comparisons among the various
IGIV products have been difﬁcult to make as true
head-to-head, brand versus brand trials have not
been carried out. Given the paucity of data, IGIV
could be considered commodity products with
equivalent efﬁcacy, incidence of adverse events on
infusion and safety. Now, IGIV-C has been com-
pared with IGIV-SD in an equivalence trial using
prevention of validated infections as a primary out-
come measure [7] among persons with PIDD. Sur-
prisingly, differences in clinical outcome were seen
even though the trial was not designed to show
superiority. Our favorable economic results for
IGIV-C corroborate the clinical differences seen in
the trial.
The manufacturing processes, safety measures to
eliminate viruses and other pathogens, formulation
and composition differ quite signiﬁcantly among
the various IGIV products [17,18]. For example,
sucrose found in some products has been considered
a risk factor for acute renal failure [18,19]. Products
that have a high osmolarity and or sodium load has
been associated with vascular thromboses [20,21].
These ﬁndings lend further support to the notion
that all IGIV products are not the same.
Stadtmauer et al. estimated costs of PIDD disease
burden to be between $17,000 and $34,000 per
patient annually. Extrapolating our 9-month $1300
per patients savings annually, switching from IGIV-
SD to IGIV-C is projected to save $1700 or 5% to
10% of annual per patient costs. Placed in this con-
text, our ﬁndings show modest reductions in per
patient costs annually.
Our study has several limitations, ﬁrst, costs
were examined retrospectively, therefore, we do not
have access to data that were not collected such as
home care visits. There may be cost differences
among the use of home health services and provid-
ers not associated with the clinical sites, which
could change our estimates of cost differences. Sec-
ond, participant self reporting bias could account
for varying resource use and therefore, our incre-
mental cost differences. Nevertheless, given that
participants were, on average, fairly compliant, had
good follow-up and the trial design was double
blinded and randomized, we believe the risk of
reporting bias is minimized. Furthermore, our ﬁnd-
ings remained robust under multiple sensitivity
analyses. A third limitation is that participants were
followed for 9 months and it is unclear if the
observed cost differences would increase or
decrease over a longer term horizon. Longer term
outcome data is needed. In evaluation of the exter-
nal validity of our study, we noticed that the age of
our patient population demographics was similar
to those reported in a national survey of PIDD in
the United States [22], however, our study enrolled
more men (59%) than reported nationally (48%).
Finally, because efﬁcacy (infection rate) and
resource use are correlated, we presume that equiv-
alence in efﬁcacy among products will negate the
estimated cost savings.
Conclusions
Assuming equal acquisition costs, we found that
PIDD participants treated with IGIV-C had lower
costs than those treated with IGIV-SD. Our results
suggest that the newer manufacturing process can
result in clinical and economic beneﬁts. Given the
high costs associated with management of PIDD,
products that optimize resource use and reduce cost
will maximize value. As clinicians and managed
care decision-makers consider use of IGIV prod-
ucts, clinical and economic differences should be
considered when making treatment and formulary
decisions.
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